breast cancer
New Strategy Proposed for HR+, HER2– Advanced Breast Cancer
In certain patients with HR+, HER2– advanced breast cancer, switching from an aromatase inhibitor to ...
AUGUST 26, 2025
ASCO Meeting: Enhertu + Perjeta Potential First-Line Combo for Metastatic Breast Cancer
Trastuzumab deruxtecan combined with Perjeta may become first-line therapy for people with metastatic HER2-positive ...
JUNE 13, 2025
First and Only Ready-to-Dilute, Multi-Dose Vial of Thiotepa Approved
The FDA approved the 100 mg/10 mL multi-dose vial of Tepylute, a ready-to-dilute formulation of thiotepa to treat ...
MAY 8, 2025
Environmental Exposure Deemed a Risk Factor for Breast Cancer
Environmental inequities are a significant contributor to breast cancer disparities among Black women, highlighting ...
MARCH 14, 2025
New Treatments Emerge for Early-Stage HR+ Breast Cancer
New treatments for early-stage hormone receptor–positive breast cancer—the most common ...
MARCH 12, 2025
FDA Approves Datroway for Unresectable or Metastatic, HR-positive, HER2-negative Breast Cancer
The FDA has approved Datroway, a Trop-2−directed antibody and topoisomerase inhibitor conjugate, for adult ...
JANUARY 22, 2025
Rise in Breast Cancer Among Young Women Requires New Models of Care
Supportive care programs can empower young women to face the unique challenges of a breast cancer diagnosis.
JANUARY 16, 2025
Is Breast Cancer Metastasis a Hereditary Disorder?
Scientists have been on a quest to identify which malignant mutations within the tumor allow rogue cells to break ...
JANUARY 16, 2025
Environmental Exposure a Risk Factor for Breast Cancer
Environmental inequities are a significant contributor to breast cancer disparities among Black women, highlighting ...
JANUARY 16, 2025
The Case for Population-Based Genetic Testing in Breast Cancer
When genetic testing guidelines were established in the 1990s, genetic tests were expensive and came with concerns ...
JANUARY 16, 2025
Kisqali With an AI and Kisqali Femara Co-Pack Approved for Early High-Risk Breast Cancer
The FDA has approved Kisqali with an aromatase inhibitor for the adjuvant treatment of adults with HR-positive, ...
SEPTEMBER 17, 2024
Sexual Dysfunction Common for Women With MBC
Self-reported sexual dysfunction is frequent in women with metastatic breast cancer, according to a recent study ...
JUNE 21, 2024
